Pleural Effusion Drug Market Report 2026

Pleural Effusion Drug Market Overview

• Pleural Effusion Drug market size has reached to $3.32 billion in 2025 • Expected to grow to $5.31 billion in 2030 at a compound annual growth rate (CAGR) of 9.9% • Growth Driver: Rising Burden Of Cardiovascular And Heart Failure Diseases Is Fueling The Growth Of The Market Due To Increasing Incidence Of Fluid Accumulation And Demand For Effective Symptom Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pleural Effusion Drug Market?

Pleural effusion drugs refer to pharmaceutical treatments used to manage and alleviate the accumulation of excess fluid in the pleural space surrounding the lungs. These drugs aim to address underlying causes such as infection, inflammation, heart failure, or malignancy while also relieving symptoms such as breathlessness and chest discomfort. The main drug types of pleural effusion drug include diuretics, antibiotics, chemotherapeutic agents, and other drug types. Diuretics refer to medications that help reduce fluid accumulation by increasing urine production and removing excess fluid from the body. The route of administration includes oral, injectable, and intrapleural. Distribution channels are categorized into hospital pharmacy, retail pharmacy, and online pharmacy, serving end users including hospitals, homecare settings, and other end-users.

What Is The Pleural Effusion Drug Market Growth Forecast?

The pleural effusion drug market size is expected to see strong growth in the next few years.It will grow to $5.31 billion by 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing adoption of targeted oncology therapies for malignant effusion, growth in precision medicine-based respiratory treatments, rising demand for minimally invasive drug delivery methods, expansion of homecare-based respiratory treatment solutions, increasing investment in biologics and advanced anti-inflammatory drugs.Major trends in the forecast period include precision medicine-based targeted therapy for pleural effusion management, biomarker-driven drug development for malignant pleural effusion treatment, advanced biologic anti-inflammatory therapies for fluid reduction in pleural space, increasing adoption of combination drug regimens for underlying cause treatment, development of long-acting injectable formulations for improved respiratory symptom control.

Global Pleural Effusion Drug Market Segmentation

1) By Drug Type: Diuretics, Antibiotics, Chemotherapeutic Agents, Other Drug Types 2) By Route Of Administration: Oral, Injectable, Intrapleural 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 4) By End-Users: Hospitals, Homecare Settings, Other End-Users Subsegments: 1) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium Sparing Diuretics, Carbonic Anhydrase Inhibitors 2) By Antibiotics: Penicillin Antibiotics, Cephalosporin Antibiotics, Macrolide Antibiotics, Fluoroquinolone Antibiotics, Tetracycline Antibiotics, Glycopeptide Antibiotics 3) By Chemotherapeutic Agents: Alkylating Agents, Antimetabolites, Plant Alkaloids, Topoisomerase Inhibitors, Antitumor Antibiotics, Targeted Therapy Agents 4) By Other Drug Types: Corticosteroids, Immunotherapy Agents, Fibrinolytic Agents, Analgesics, Antifungal Agents, Antiviral Agents

What Are The Drivers Of The Pleural Effusion Drug Market?

The growing burden of cardiovascular and heart failure diseases is expected to propel the growth of the pleural effusion drug industry going forward.Cardiovascular diseases and heart failure are conditions in which the heart and blood vessels are impaired, leading to complications such as heart attacks, stroke, and fluid accumulation in the lungs.The burden of cardiovascular and heart failure diseases is rising primarily due to aging populations, as age-related decline in heart and vascular function increases susceptibility to chronic cardiovascular conditions.Pleural effusion drugs help manage cardiovascular and heart failure diseases' burden by reducing fluid accumulation in the pleural space, improving patient outcomes, and enhancing quality of life.For instance, in September 2025, according to the American College of Cardiology, a United States–based professional medical organization, deaths due to cardiovascular diseases globally reached approximately 19.2 million in 2023, up from 13.1 million in 2022.Therefore, the growing burden of cardiovascular and heart failure diseases is driving the growth of the pleural effusion drug industry. The increasing healthcare expenditure is expected to propel the growth of the pleural effusion drug industry going forward.Healthcare expenditure refers to the total spending by governments, insurers, and individuals on medical goods, services, and public health activities.The rising healthcare expenditure is largely driven by an aging population and increased utilization of health care services, as greater demand for medical care leads to higher overall spending across public and private payers.The growing healthcare expenditure directly boosts the need for pleural effusion drugs, as higher funding enables broader patient access to specialized drugs and therapies used in managing conditions such as pleural effusion.For instance, in April 2025, according to the Office for National Statistics, a UK-based independent producer of official statistics, in 2024, the UK’s healthcare spending reached around £317 billion, reflecting a 6.5% nominal increase compared with 2023.Therefore, increasing healthcare expenditure is driving the growth of the pleural effusion drug industry.

Key Players In The Global Pleural Effusion Drug Market

Major companies operating in the pleural effusion drug market are Merck & Co. Inc., Pfizer Inc., AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Cipla Limited, Simcere Pharmaceutical Group Limited, Gongwin Biopharm Holdings Co. Ltd., F. Hoffmann-La Roche Ltd., Wuhan YZY Biopharma Co. Ltd., Lipac Oncology LLC, RS Oncology LLC, Genelux Corporation, Jiangxi Jemincare Group Co. Ltd., Biosyngen Pte. Ltd., Aileron Therapeutics Inc., Rusoma

What Are Latest Mergers And Acquisitions In The Pleural Effusion Drug Market?

In October 2023, Aileron Therapeutics, Inc., a US-based biopharmaceutical company, acquired Lung Therapeutics, Inc. Through this acquisition, Aileron gained clinical-stage candidates such as LTI‑01, a drug specifically developed for loculated pleural effusions, allowing the company to strengthen its pulmonary therapeutics pipeline and continue development of these assets into 2024 and beyond. Lung Therapeutics, Inc. is a US-based biopharmaceutical company that is involved in developing drugs for pleural effusion.

Regional Insights

North America was the largest region in the pleural effusion drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pleural Effusion Drug Market?

The pleural effusion drug market consists of sales of pleurodesis agents, corticosteroids, bronchodilators, and antifungal medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

What is the Market Assessment and Strategic Outlook for the Pleural Effusion Drug Industry?

The pleural effusion drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pleural effusion drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

What is the Market Assessment and Strategic Outlook for the Pleural Effusion Drug Market Report 2026?

The pleural effusion drug market research report is one of a series of new reports from The Business Research Company that provides pleural effusion drug market statistics, including pleural effusion drug industry global market size, regional shares, competitors with a pleural effusion drug market share, detailed pleural effusion drug market segments, market trends and opportunities, and any further data you may need to thrive in the pleural effusion drug industry. This pleural effusion drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.